 |
|
Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001
Fangjun Zhou, PhD;
Jeanne Santoli, MD, MPH;
Mark L. Messonnier, PhD;
Hussain R. Yusuf, MBBS, MPH;
Abigail Shefer, MD;
Susan Y. Chu, PhD, MSPH;
Lance Rodewald, MD;
Rafael Harpaz, MD, MPH
Arch Pediatr Adolesc Med. 2005;159:1136-1144.
Objective To evaluate the economic impact of the routine US childhood immunization schedule: diphtheria and tetanus toxoids and acellular pertussis; tetanus and diphtheria toxoids; Haemophilus influenzae type b conjugate; inactivated poliovirus; measles, mumps, and rubella; hepatitis B; and varicella vaccines.
Design Decision tree–based analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported for 1995-2001. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and time lost. All costs were inflated to 2001 US dollars, and all costs and benefits in the future were discounted at a 3% annual rate.
Participants A hypothetical 2001 US birth cohort of 3 803 295 infants was followed up from birth through death.
Main Outcome Measures Net present value (net savings) and benefit-cost ratios of routine immunization.
Results Routine childhood immunization with the 7 vaccines was cost saving from the direct cost and societal perspectives, with net savings of $9.9 billion and $43.3 billion, respectively. Without routine vaccination, direct and societal costs of diphtheria, tetanus, pertussis, H influenzae type b, poliomyelitis, measles, mumps, rubella, congenital rubella syndrome, hepatitis B, and varicella would be $12.3 billion and $46.6 billion, respectively. Direct and societal costs for the vaccination program were an estimated $2.3 billion and $2.8 billion, respectively. Direct and societal benefit-cost ratios for routine childhood vaccination were 5.3 and 16.5, respectively.
Conclusion Regardless of the perspective, the current routine childhood immunization schedule results in substantial cost savings.
Author Affiliations: National Immunization Program, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Ga. Dr Yusuf is now with UNICEF, New Delhi, India.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Financing Vaccines: Cornerstone of Prevention
Gellin and Shen
Pediatrics 2009;124:S457-S458.
FULL TEXT
Net Financial Gain or Loss From Vaccination in Pediatric Medical Practices
Coleman et al.
Pediatrics 2009;124:S472-S491.
ABSTRACT
| FULL TEXT
Health Insurance Plans and Immunization: Assessment of Practices and Policies, 2005-2008
Hunsaker et al.
Pediatrics 2009;124:S532-S539.
ABSTRACT
| FULL TEXT
Financing the Delivery of Vaccines to Children and Adolescents: Challenges to the Current System
Lindley et al.
Pediatrics 2009;124:S548-S557.
ABSTRACT
| FULL TEXT
Industry Perspectives: Ensuring Vaccination of Children and Adolescents Without Financial Barriers
Feinberg and Gordon
Pediatrics 2009;124:S563-S564.
FULL TEXT
Development of the Pediatric Environmental Health Specialty Unit Network in North America
Paulson et al.
AJPH 2009;99:S511-S516.
ABSTRACT
| FULL TEXT
OR Practice--Catch-Up Scheduling for Childhood Vaccination
Engineer et al.
Operations Research 2009;57:1307-1319.
ABSTRACT
Vaccine Adherence in Adolescents
Lehmann and Benson
CLIN PEDIATR 2009;48:801-811.
ABSTRACT
A Stepped Intervention Increases Well-Child Care and Immunization Rates in a Disadvantaged Population
Hambidge et al.
Pediatrics 2009;124:455-464.
ABSTRACT
| FULL TEXT
Necessary Innovations in Immunization Delivery
Davis and Shah
Arch Pediatr Adolesc Med 2009;163:483-485.
FULL TEXT
Preventing Vaccine-Preventable Diseases in Low-Resource Communities
Rodewald and Markowitz
Arch Pediatr Adolesc Med 2009;163:487-488.
FULL TEXT
A Closer Look at the Economic Argument for Disease Prevention
Woolf
JAMA 2009;301:536-538.
FULL TEXT
Projected Cost-effectiveness of New Vaccines for Adolescents in the United States
Ortega-Sanchez et al.
Pediatrics 2008;121:S63-S78.
ABSTRACT
| FULL TEXT
Delivering New Vaccines to Adolescents: The Role of School-Entry Laws
Horlick et al.
Pediatrics 2008;121:S79-S84.
ABSTRACT
| FULL TEXT
Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Roush et al.
JAMA 2007;298:2155-2163.
ABSTRACT
| FULL TEXT
Recent Developments in Health Law
Gerber et al.
J Law Med Ethics 2007;35:495-507.
Should all children be immunised against hepatitis A?
Temte
BMJ 2006;332:715-718.
FULL TEXT
|
